Chronic Heart Failure Updates at ACC 2022: Important New Findings for HFrEF and HFpEF*

In patients with HFpEF, sacubitril/valsartan attenuated the rate of decline in renal outcomes similarly in patients with and without diabetes compared to valsartan alone.

In ambulatory patients with heart failure, low-sodium diet showed a modest quality-of-life benefit and improvement in NYHA class, but no improvement in all-cause mortality or CV-related hospitalizations.